Skip to content
Disopyramide
Norpace (disopyramide) is a small molecule pharmaceutical. Disopyramide was first approved as Norpace on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, cardiac arrhythmias, and ventricular premature complexes in the USA. It is known to target potassium voltage-gated channel subfamily H member 2 and alpha-1-acid glycoprotein 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Norpace (generic drugs available since 1985-02-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Disopyramide phosphate
Tradename
Company
Number
Date
Products
NORPACEMylanN-017447 RX1982-01-01
2 products, RLD, RS
NORPACE CRMylanN-018655 RX1982-07-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
disopyramide phosphateANDA2022-04-28
norpace norpace crNew Drug Application2020-12-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiac arrhythmiasEFO_0004269D001145I49.9
ventricular premature complexes—D018879I49.3
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BA: Antiarrhythmics, class ia
— C01BA03: Disopyramide
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDISOPYRAMIDE
INNdisopyramide
Description
Disopyramide is a monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of pyridines and a tertiary amino compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
Identifiers
PDB3APW
CAS-ID3737-09-5
RxCUI3541
ChEMBL IDCHEMBL517
ChEBI ID4657
PubChem CID3114
DrugBankDB00280
UNII IDGFO928U8MQ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNH2
KCNH2
ORM2
ORM2
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
3757
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Q9H3P0
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35219)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,339 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8 adverse events reported
View more details